BEHRENS M KATHLEEN

Average Profitability
39.75%
Insider Buys Quantity
13
Insider Buys Sum
$15.16M
Insider Sells Quantity
2
Insider Sells Sum
$1.79M

Insider Activity of BEHRENS M KATHLEEN

The largest purchase of all time was on 2020-12-11 and amounted to 66666 shares of IGM Biosciences, Inc. for $4M.

The largest sale of all time was on 2018-10-31 and amounted to 20000 shares of Sarepta Therapeutics, Inc. for $1.36M.

Biography of BEHRENS M KATHLEEN

No biography is available at this moment.

2023-06-26PurchaseIGM Biosciences, Inc.
IGMS
director
112,500
0.2244%
$8.00$900,000-7.21%
2022-11-08PurchaseIGM Biosciences, Inc.
IGMS
director
60,000
0.1352%
$17.14$1.03M-34.1%
2022-03-31PurchaseIGM Biosciences, Inc.
IGMS
43,478
0.0852%
$23.00$999,994-26.49%
2021-03-10SaleSarepta Therapeutics, Inc.
SRPT
director
5,000
0.0064%
$85.76$428,800-6.73%
2020-12-11PurchaseIGM Biosciences, Inc.
IGMS
director
66,666
0.1472%
$60.00$4M-13.42%
2020-09-10PurchaseIGM Biosciences, Inc.
IGMS
director
60,000
0.1968%
$60.78$3.65M+29.51%
2019-12-09PurchaseIGM Biosciences, Inc.
IGMS
director
20,000
0.0634%
$24.87$497,316+114.56%
2019-09-18PurchaseIGM Biosciences, Inc.
IGMS
director
125,000
1.9493%
$16.00$2M+104.4%
2019-09-06PurchaseSarepta Therapeutics, Inc.
SRPT
director
2,500
0.0035%
$87.98$219,950+39.98%
2018-10-31SaleSarepta Therapeutics, Inc.
SRPT
director
20,000
0.0153%
$67.83$1.36M-9.52%
2016-03-16PurchaseSarepta Therapeutics, Inc.
SRPT
director
10,000
0.0219%
$14.54$145,433+91.13%
2016-03-14PurchaseSarepta Therapeutics, Inc.
SRPT
director
65,000
0.1414%
$16.54$1.08M+66.5%
2013-09-16PurchaseSarepta Therapeutics, Inc.
SRPT
director
6,500
0.0195%
$37.04$240,778-27.75%
2012-09-07PurchaseSarepta Therapeutics, Inc.
SRPT
director
17,500
0.0756%
$14.73$257,724+107.97%
2011-04-06PurchaseSarepta Therapeutics, Inc.
SRPT
director
100,000
0.0708%
$1.50$150,000-27.53%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.